Latest Period
Q4 2025
Security Snapshot
KIORA PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (KPRX) Institutional Ownership
CUSIP: 49721T507
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
19
Shares (Excl. Options)
706,945
Price
$1.97
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- KPRX on Nasdaq
- Shares outstanding
- 3,938,449
- Price per share
- $1.96
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 706,945
- Total reported value
- $1,392,679
- % of total 13F portfolios
- 0%
- Share change
- +90,776
- Value change
- +$165,896
- Number of holders
- 19
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KPRX - KIORA PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share is tracked under CUSIP 49721T507.
- 19 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 19 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $1,392,679 to $498.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 19 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 49721T507?
CUSIP 49721T507 identifies KPRX - KIORA PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 49721T507:
Significant Owners of KIORA PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (KPRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 9.9% | $1,095,537 | 365,179 | ADAR1 Capital Management GP, LLC | 30 Jun 2025 | |||
| Nantahala Capital Management, LLC | 10% | 0% | $1,018,394 | +$160,860 | 363,712 | +19% | Nantahala Capital Management, LLC | 30 Sep 2025 |
| HIRSCHMAN ORIN | 4.9% | -40% | $380,178 | -$123,265 | 192,984 | -24% | Orin Hirschman | 31 Dec 2025 |
| Nantahala Capital Partners Limited Partnership | 5.3% | $569,115 | 189,705 | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 08 Aug 2025 | |||
| Alyeska Investment Group, L.P. | 2.5% | $249,572 | 75,628 | Alyeska Investment Group, L.P. | 31 Dec 2024 | |||
| GOLDMAN SACHS GROUP INC | 0% | $429 | 130 | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2024 |
As of 31 Dec 2025, 19 institutional investors reported holding 706,945 shares of KIORA PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (KPRX). This represents 18% of the company’s total 3,938,449 outstanding shares.
Top 21 Institutional Shareholders
The largest institutional shareholders of KIORA PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (KPRX) together control 18% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 4.3% | 167,941 | 0% | 0.02% | $330,844 |
| Stonepine Capital Management, LLC | 3.3% | 131,144 | -6.7% | 0.21% | $258,354 |
| DRW Securities, LLC | 2.8% | 110,282 | +199% | 0.02% | $217,255 |
| Nantahala Capital Management, LLC | 2.7% | 106,156 | -32% | 0.01% | $209,127 |
| Alyeska Investment Group, L.P. | 2% | 76,904 | 0% | $151,501 | |
| VANGUARD GROUP INC | 0.84% | 33,091 | +58% | 0% | $65,189 |
| CITADEL ADVISORS LLC | 0.57% | 22,381 | -50% | 0% | $44,091 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.56% | 22,010 | +17% | 0% | $43,359 |
| RENAISSANCE TECHNOLOGIES LLC | 0.54% | 21,200 | +71% | 0% | $41,764 |
| XTX Topco Ltd | 0.3% | 11,971 | 0% | $23,583 | |
| Tower Research Capital LLC (TRC) | 0.04% | 1,584 | 0% | $3,120 | |
| MILLER WEALTH ADVISORS, LLC | 0.03% | 1,000 | 0% | $1,970 | |
| UBS Group AG | 0.02% | 912 | -33% | 0% | $1,797 |
| SBI Securities Co., Ltd. | 0.01% | 256 | 0% | 0% | $504 |
| BlackRock, Inc. | 0% | 58 | 0% | 0% | $114 |
| BANK OF AMERICA CORP /DE/ | 0% | 29 | +16% | 0% | $57 |
| NewEdge Advisors, LLC | 0% | 22 | 0% | 0% | $43 |
| OSAIC HOLDINGS, INC. | 0% | 2 | 0% | 0% | $3 |
| Activest Wealth Management | 0% | 2 | 0% | 0% | $4 |
| TWO SIGMA INVESTMENTS, LP | 0% | 0 | -100% | $0 | |
| CITIGROUP INC | 0% | 0 | -100% | $0 |
Institutional Holders of KIORA PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (KPRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 258 | $498 | $1.96 | 2 | |
| 2025 Q4 | 706,945 | $1,392,679 | +$165,896 | $1.97 | 19 |
| 2025 Q3 | 616,169 | $1,714,712 | -$910,084 | $2.78 | 17 |
| 2025 Q2 | 931,843 | $2,683,707 | -$1,054,952 | $2.88 | 16 |
| 2025 Q1 | 1,285,403 | $3,869,063 | +$78,079 | $3.01 | 18 |
| 2024 Q4 | 1,259,459 | $4,164,082 | +$76,847 | $3.30 | 16 |
| 2024 Q3 | 1,213,569 | $4,441,661 | +$905,961 | $3.66 | 18 |
| 2024 Q2 | 966,044 | $4,057,360 | +$4,057,360 | $4.20 | 15 |